Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1996 6
1997 1
1998 2
1999 2
2000 6
2001 3
2002 5
2003 7
2004 5
2005 7
2006 5
2007 2
2008 3
2009 3
2010 2
2011 4
2012 3
2013 2
2014 3
2015 6
2016 4
2017 6
2018 5
2019 4
2020 2
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27141389

99 results

Results by year

Filters applied: . Clear all
Page 1
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.
Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, Suutari T, Bunker A, Yliperttula M, Urtti A, Cerullo V. Capasso C, et al. Oncoimmunology. 2015 Oct 29;5(4):e1105429. doi: 10.1080/2162402X.2015.1105429. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141389 Free PMC article.
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article.
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Ylösmäki E, et al. Mol Ther Oncolytics. 2021 Feb 10;20:459-469. doi: 10.1016/j.omto.2021.02.006. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33718594 Free PMC article.
99 results